Publications by authors named "Mª Del Carmen Alamo"
Background: The combination of and inhibitors delays the onset of resistance and provides more sustained and dramatic responses in comparison with a inhibitor in monotherapy. The objective of the study was to evaluate the effectiveness of the combination therapy with vemurafenib/cobimetinib in terms of durability, and to describe differential characteristics in patients associated to durable responses in real-world settings.
Patients And Methods: Retrospective, observational, cross-sectional, multicenter study involving 41 patients with advanced melanoma harboring a mutation who initiated a combination therapy with vemurafenib/cobimetinib between May 2018 and March 2019.
Different Pathological Complete Response Rates According to PAM50 Subtype in HER2+ Breast Cancer Patients Treated With Neoadjuvant Pertuzumab/Trastuzumab vs. Trastuzumab Plus Standard Chemotherapy: An Analysis of Real-World Data.
Tamara Díaz-Redondo Rocio Lavado-Valenzuela Begoña Jimenez Tomas Pascual Fernando Gálvez Maria Del Carmen Alamo
Front Oncol
November 2019
Article Synopsis
- The study investigates the effectiveness of combining pertuzumab and trastuzumab with chemotherapy in HER2-positive early breast cancer patients, comparing two treatment cohorts from eight Spanish hospitals.
- Data shows that the cohort receiving both pertuzumab and trastuzumab had a higher rate of pathological complete response (pCR) at 61% compared to 39% for those receiving trastuzumab alone.
- Results indicate that this enhanced treatment significantly increases pCR rates, particularly for HER2-enriched and luminal subtypes, but shows no advantage for basal-like tumors.